Investors Face August Deadline in ADMA Biologics Fraud Lawsuit

The legal complaint alleges that ADMA Biologics misled shareholders by concealing related-party transactions and inflating revenue figures through channel stuffing. According to the filing, the company’s internal controls were insufficient to prevent these practices, rendering public statements regarding operations and business health materially inaccurate throughout the specified period.

Shareholders affected by the stock's performance during this timeframe may contact the Law Offices of Frank R. Cruz to join the litigation. While participation in the class action does not require immediate action, those seeking to serve as lead plaintiff must file their motions by the August 10 deadline. The firm is requesting that interested parties provide their contact information and purchase history to facilitate the review of their claims.